Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 10.13
- Piotroski Score 3.00
- Grade Sector Outperform
- Symbol (TWST)
- Company Twist Bioscience Corporation
- Price $41.63
- Changes Percentage (1.26%)
- Change $0.52
- Day Low $39.81
- Day High $42.99
- Year High $60.90
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/18/2024
- Fiscal Year End N/A
- Average Stock Price Target $45.00
- High Stock Price Target $53.00
- Low Stock Price Target $32.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.36
- Trailing P/E Ratio -15.02
- Forward P/E Ratio -15.02
- P/E Growth -15.02
- Net Income $-208,726,000
Income Statement
Quarterly
Annual
Latest News of TWST
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Twist Bioscience Corp (TWST) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...
Twist Bioscience Corp's 2025 guidance doesn't include MRD growth, indicating uncertainty. Express Genes expects a 50% gross margin by Q4. Minimal exposure to NIH budgets gives a competitive edge. Next...
By Yahoo! Finance | 2 days ago -
Twist Bioscience Corporation (TWST): Among the Worst ARK Stocks According to Short Sellers
This article discusses the performance of Twist Bioscience Corporation (NASDAQ:TWST) as an ARK stock and its potential in the gene editing industry. It also highlights Cathie Wood's investment strateg...
By Yahoo! Finance | 2 months ago -
Twist Bioscience Corporation (TWST) Stock Price, News, Quote & History
Twist Bioscience Corporation produces and sells synthetic DNA-based products for various industries like healthcare, agriculture, and research. Their offerings include synthetic genes, oligo pools, NG...
By Yahoo! Finance | 3 months ago
